Boehringer, LEO ink deal for IL-36 drug; Bayer’s Kerendia gets another indication

Plus, news about Illimis Therapeutics and Azurity: Boehringer Ingelheim, LEO Pharma sign €90M upfront pact: The deal focuses on Spevigo, an IL-36 drug approved to treat generalized pustular psoriasis. LEO will ...